U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
23 déc. 2023 04h47 HE
|
Zealand Pharma
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection...
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
22 déc. 2023 04h30 HE
|
Zealand Pharma
Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S...
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
22 déc. 2023 02h00 HE
|
Zealand Pharma
Press release No. 17 / 2023 Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank Copenhagen, Denmark, December 22, 2023 – Zealand Pharma...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
07 déc. 2023 16h05 HE
|
Zealand Pharma
Company announcement – No. 44 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
07 déc. 2023 16h00 HE
|
Zealand Pharma
Company announcement – No. 43 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, December 7, 2023 – Zealand Pharma A/S...
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
04 déc. 2023 02h30 HE
|
Zealand Pharma
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
04 déc. 2023 02h00 HE
|
Zealand Pharma
Company announcement – No. 42 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Total number of shares and voting rights in Zealand Pharma at November 30, 2023
30 nov. 2023 11h15 HE
|
Zealand Pharma
Company announcement – No. 41 / 2023 Total number of shares and voting rights in Zealand Pharma at November 30, 2023 Copenhagen, Denmark, November 30, 2023 – Zealand Pharma A/S...
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
30 nov. 2023 02h00 HE
|
Zealand Pharma
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no....
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
16 nov. 2023 16h00 HE
|
Zealand Pharma
Company announcement – No. 39 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, November 16, 2023 – Zealand Pharma...